Effects of Tart Cherry and Aroniaberry Suplementation on Endothelial Function and Cardiovascular Measures in Healthy Older Adults-Tests of Plasma and Serum

This is a combined synopsis/solicitation for commercial services prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The solicitation number for this requirement is NIH-OD4289832 and this is a Request for Proposals (RFP). The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-88-1 dated June 15, 2016. The NAICS code for this requirement is 541690 for $15.0M. The Statement of Work is attached. The Period of Performance will be November 1, 2016 through October 31, 2017 for the base year and two (2), twelve month option periods. FAR Pt. 52.212-1, Instructions to Offerors-Commercial, applies to this acquisition and a statement regarding any addenda to the provision. FAR Pt. 52.212-2, Evaluation-Commercial Items is applicable. Deliverables Six tests to be performed on approximately 576 samples of either the plasma or serum samples Testing results will be returned within two weeks from the receipt of the sample. Results should be provided in both hard copy and electronic format Contractor will be responsible for providing the appropriate test forms, specimen supplies, tubes, or other appropriate items for the collection and ordering of laboratory tests. Shipping costs and shipping supplies will also be provided by the contractor at no additional costs. Contractor shall provide novel biomarker technologies through a College of American Pathologists (CAP)- accredited, Clinical Laboratory Improvement Amendments (CLIA)- certified clinical reference laboratory. Contractor will provide licensure, permits and registration numbers for certification. Contractor must provide scientifically proven and medically relevant biomarker diagnostic tests Contractor must notify the Project Officer within 24 hours of receipt of any samples if the product was not viable for testing with an explanation/reason as to why. Proposals will be evaluated on: Evaluation Criteria The government will be evaluating the proposals on a best value basis using Tradeoffs. The evaluation factors are listed below, with the weight of each factor attributed each Non-Price Factor. Non-Price Factors, when combined, are significantly more important than Price Factor. Laboratory Qualifications- Adequacy and feasibility of the proposed professional staff to conduct the services and meet research goals and objectives Adequacy and feasibility to establish and maintain sensitivity and accuracy Price will be rated only among those proposals that are deemed Technically Acceptable after review of their Non-Price Factors. Offerors shall include a completed copy of the provision at 52.212-3, Offerors Representations and Certifications-Commercial Items, with its offer or submit a printout to their Online Reps and Certs. The clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in SAM at www.sam.gov prior to award, during performance and through final payment of the Purchase Order. Requests for information and (or) questions concerning this requirement are to be submitted by- Tuesday, November 15,2016 by e-mail Only. Offers must be submitted no later than 5:00 P.M. Eastern Daylight Time on Wednesday, November 16, 2016. For Delivery responses through the Postal Service, the address is National Institute of Health,Office of Logistics and Acquisition Operations, 6011 Executive Blvd. 5th Floor, Rockville, MD 20892, E-mail submissions are permitted to ellent@od.nih.gov.